SCHEMBL1000783

SCHEMBL1000783

CC(C)Oc1ccc(NC(=O)c2cccc(S(=O)(=O)N3C[C@H]4C[C@@H]3CO4)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ELOVL6 Q9H5J4 5/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
CYP2C9 P11712 1/20 0.46
NAMPT P43490 1/20 0.46
HTT P42858 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 1/20 0.43
LMNA P02545 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPK1 P28482 3/20 0.43
GAA P10253 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 3/20 0.43
USP2 O75604 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1000753 1.00 ELOVL6 (0.49) ELOVL6MEN1KMT2ACYP2C9NAMPT
SCHEMBL1001405 0.84 ELOVL6 (0.56) ELOVL6MEN1KMT2AHTTL3MBTL1
SCHEMBL1001242 0.84 ELOVL6 (0.61) ELOVL6MEN1KMT2AHTT
SCHEMBL999626 0.83 ELOVL6 (0.59) ELOVL6MEN1KMT2AHTTL3MBTL1
Trifluoroacetic Acid SCHEMBL1000613 0.81 ELOVL6 (0.49) ELOVL6MEN1KMT2AHTTL3MBTL1
SCHEMBL1001481 0.78 KMT2A (0.56) ELOVL6MEN1KMT2AHTTL3MBTL1
SCHEMBL1001743 0.78 KMT2A (0.56) ELOVL6MEN1KMT2AHTTL3MBTL1
SCHEMBL1001294 0.77 LMNA (0.44) MEN1KMT2ACYP2C9NAMPTHTT
SCHEMBL1001582 0.76 KMT2A (0.80) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL1000747 0.76 KMT2A (0.64) MEN1KMT2AHTTL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 ELOVL6 2/4885MEN1 4600/4885KMT2A 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.